Less than two years after Horizon Pharma $HZNP procured phase III-ready thyroid eye disease (TED) drug teprotumumab for $145 million upfront by acquiring a unit of Narrow River, biotech veteran David Madden’s investment firm — the bet has paid off, as the autoimmune inflammatory disorder drug passed its late-stage test on Thursday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,